Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Tango Therapeutics (TNGX) EBT Margin: 2020-2025

Historic EBT Margin for Tango Therapeutics (TNGX) over the last 5 years, with Sep 2025 value amounting to 29.50%.

  • Tango Therapeutics' EBT Margin rose 28032.00% to 29.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -150.99%, marking a year-over-year increase of 13296.00%. This contributed to the annual value of -309.24% for FY2024, which is 3106.00% down from last year.
  • Per Tango Therapeutics' latest filing, its EBT Margin stood at 29.50% for Q3 2025, which was up 102.42% from -1,220.31% recorded in Q2 2025.
  • In the past 5 years, Tango Therapeutics' EBT Margin ranged from a high of 29.50% in Q3 2025 and a low of -1,220.31% during Q2 2025.
  • Moreover, its 3-year median value for EBT Margin was -485.74% (2023), whereas its average is -473.44%.
  • Its EBT Margin has fluctuated over the past 5 years, first surged by 28,926bps in 2023, then slumped by 109,208bps in 2025.
  • Quarterly analysis of 5 years shows Tango Therapeutics' EBT Margin stood at -382.59% in 2021, then slumped by 6,990bps to -452.49% in 2022, then slumped by 11,308bps to -565.57% in 2023, then plummeted by 34,823bps to -913.80% in 2024, then skyrocketed by 28,032bps to 29.50% in 2025.
  • Its EBT Margin was 29.50% in Q3 2025, compared to -1,220.31% in Q2 2025 and -738.91% in Q1 2025.